Harness Genetic Medicine for Treatment of Rare & Common Eye Diseases

Ophthalmic drug developers are unlocking the full potential of gene therapy. Crucial lessons learnt from both clinical successes and failures, coupled with recent improvements in development and delivery, means that the space is poised to capitalize on the significant potential of the eye as a target for genetic medicine approaches.

The 5th Gene Therapy for Ophthalmic Disorders Summit will unite 100+ industry leaders to showcase the latest innovations across vector engineering, routes of administration, preclinical modelling, and biomarker endpoint selection alongside learnings of successful later-stage clinical trials to advance more effective and safe genetic therapies to transform eye disease treatment.